Related references
Note: Only part of the references are listed.Antibody-Drug Conjugates: A Comprehensive Review
Puregmaa Khongorzul et al.
MOLECULAR CANCER RESEARCH (2020)
Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies
Hao Xie et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy
Kenji Ikemura et al.
FRONTIERS IN PHARMACOLOGY (2017)
The influence of proton pump inhibitors and other commonly used medication on the gut microbiota
Floris Imhann et al.
GUT MICROBES (2017)
A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
Li-Yuan Yu et al.
ADVANCES IN THERAPY (2017)
Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study
Kenji Ikemura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Celecoxib exerts antitumor effects in HL-60 acute leukemia cells and inhibits autophagy by affecting lysosome function
Ying Lu et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer
Hongwen Li et al.
CANCER BIOLOGY & THERAPY (2016)
Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors
Zhi-Cheng Yang et al.
CURRENT DRUG METABOLISM (2016)
HER2-targeted antibody drug conjugates for ovarian cancer therapy
Jing Jiang et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Mechanisms of Resistance to Antibody-Drug Conjugates
Frank Loganzo et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3
Kenji Ikemura et al.
DRUG METABOLISM AND DISPOSITION (2016)
Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors
David J. Reeves et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Effect of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Omeprazole Plasma Pharmacokinetics in Healthy Adults
Rene A. Braeckman et al.
DRUGS IN R&D (2014)
Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development
Gillian S. Smelick et al.
MOLECULAR PHARMACEUTICS (2013)
Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects
Mohammad Niazi et al.
Drugs in research & development (2013)
Lysosomal Acidification Mechanisms
Joseph A. Mindell
ANNUAL REVIEW OF PHYSIOLOGY, VOL 74 (2012)
Efficacy of esomeprazole in treating acid-related diseases in Japanese populations
Mitsushige Sugimoto et al.
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY (2012)
Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy
Kunihiro Suzuki et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Review article: the clinical pharmacology of proton pump inhibitors
G Sachs et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs
F Luciani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Share Paper
